FINDINGS OF SCIENTIFIC MISCONDUCT

NIH GUIDE, Volume 24, Number 40, November 24, 1995



P.T. 34



Keywords:

  Ethics/Values in Science & Technol 

  Grants Administration/Policy+ 



Department of Health and Human Services



Notice is hereby given that the Office of Research Integrity (ORI)

has made final findings of scientific misconduct in the following

case:



Nicholas Y. Lorenzo, M.D., Mayo Foundation:  On October 16, 1995, ORI

found that Nicholas Y. Lorenzo, M.D., formerly of the Mayo

Foundation, committed scientific misconduct by falsifying and

fabricating data incorporated in an abstract submitted for

presentation at a professional meeting; the research was supported by

a Public Health Service (PHS) grant.



Dr. Lorenzo has entered into a Voluntary Exclusion Agreement with ORI

in which he has accepted ORI's finding and has agreed to exclude

himself voluntarily, for the three year period beginning October 16,

1995, from:



(1) any contracting or subcontracting with any agency of the United

States Government and from eligibility for, or involvement in,

nonprocurement transactions (e.g., grants and cooperative agreements)

of the United States Government, as defined in 45 CFR Part 76 and 48

CFR Subparts 9.4 and 309.4 (Debarment Regulations); and



(2) serving in any advisory capacity to PHS, including but not

limited to service on any PHS advisory committee, board, and/or peer

review committee, or as a consultant.



The above voluntary exclusion, however, shall not apply to Dr.

Lorenzo's future training or practice of clinical medicine whether as

a medical student, resident, fellow, or licensed practitioner unless

that practice involves research or research training.



The abstract was withdrawn prior to publication, and thus, no

correction of the literature is required.



Weishu Y. Weiser, Ph.D., Harvard Medical School: On October 19, 1995,

ORI found that Weishu Y. Weiser, Ph.D., formerly of the Harvard

Medical School at Brigham and Women's Hospital, committed scientific

misconduct by falsifying data in biomedical research supported by two

Public Health Service (PHS) grants.



Dr. Weiser has entered into a Voluntary Exclusion Agreement with ORI

in which she has accepted ORI's finding and has agreed to exclude

herself voluntarily, for the three year period beginning October 19,

1995, from:



(1) participating in any Federal contracts or subcontracts and from

eligibility for or involvement in Federal nonprocurement transactions

(e.g., grants and cooperative agreements), as covered in 45 CFR Part

76 and 48 CFR Subparts 9.4 and 309.4 (Debarment Regulations); and



(2) serving in any advisory capacity to PHS, including but not

limited to service on any PHS advisory committee, board, and/or peer

review committee, or as a consultant.



She has agreed to submit a letter to the Journal of Immunology and to

the Proceedings of the National Academy of Sciences to retract the

articles entitled "Human recombinant migration inhibitory factor

activates human macrophages to kill Leishmania donovani" (Journal of

Immunology 147:2006-2011, 1991), "Recombinant migration inhibitory

factor induces nitric oxide synthase in murine macrophages" (Journal

of Immunology 150:1908-1912, 1993), and "Recombinant human migration

inhibitory factor has adjuvant activity" (Proceedings of the National

Academy of Sciences 89:8049-8052, 1992).



INQUIRIES



For further information contact:



Director, Division of Research Investigations

Office of Research Integrity

5515 Security Lane, Suite 700

Rockville, MD  20852

Telephone:  (301) 443-5330



.

Return to 1995 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)